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Background: Artemisia annua L. has been used for many centuries in Chinese traditional medicine. Artemisinin, the
active principle was first isolated and identified in the 1970s becoming the global back bone to the fight against
malaria. Our research group previously developed an economic and ecological friendly process to obtain this
compound. In the pursuit to also exploit the residue generated throughout the process we further evaluated the
pharmacological potential of that extract.
Methods: The alcoholic crude extract after artemisinin precipitation maintained an enriched sesquiterpene lactones
content with residue artemisinin (1.72%) and deoxyartemisinin (0.31%), used as chemical markers for this sample.
This study evaluated the pharmacological potential of the enriched sesquiterpene lactone fraction (Lac-FR) on
different nociceptive and inflammatory experimental animal models. Previous findings on the biological properties
of lactones obtained from natural products permitted us to explore the antinociceptive activities of these compounds
based on in vivo chemical-induced behavioral assays.
Results: The enriched sesquiterpene lactone fraction (Lac-FR) was administrated by intraperitoneal injection producing
a relevant reduction in the reaction time of the animals in both phases of the formalin test, significantly reduced the
sensitivity to mechanical allodynia stimulus, reduced the paw edema caused by carrageenan injection and promoted
high antinociceptive activity in tail flick model suggesting relationship with the opioid system. Further studies are being
undertaken to elucidate the active components involved with the antinociceptive activity as well as evaluation of
synergy effect that is seen by combination of substances that is greater than would be expected from consideration
of individual contributions.
Conclusion: For the first time, results presented herein provided consistent data to support the potential use of
these lactones for pain relief as revealed by chemical-induced nociception assays in mice.Background
There has been a substantial amount of research into
the use of plants in folk-medicine, which typically high-
light the importance of members of the Asteraceae family
[1]. The genus Artemisia comprises over 400 species, many
of which have an aromatic, bitter taste [2]. The herb
Artemisia annua L. has been used for many centuries in
Chinese traditional medicine as a treatment for fever and
malaria [3,4].
Sesquiterpene lactones (SLs) are a group of secondary
metabolites found across the plant kingdom comprising* Correspondence: fabricioffavero@gmail.com
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article, unless otherwise stated.a large group of over 5000 known compounds, being
most common in families such as Cactaceae, Solanaceae,
Araceae, and the Euphorbiaceae. However they are most
prevalent in the Asteraceae, where they can be found
ubiquitously [1,5].
According to Mefort (2011) [6] sesquiterpene lactones
are the most prevalent and biologically significant sec-
ondary metabolites since they are involved in a wide
array of biological activities. Their structural diversity
and variety of biological activities such as anticancer,
anti-inflammatory, anti-tumor, anti-malarial, antiviral, anti-
bacterial, antifungal etc. have prompted interest among
chemists towards drug discovery research [1,5].
In 1971, Chinese chemists identified artemisinin, a
sesquiterpene lactone, isolated from leaves of Artemisad Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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denominated qinghaosu (QHS, artemisinin). This com-
pound bears a peroxide group that unlike most other
antimalarials, lacks a nitrogen-containing heterocyclic
ring system [3].
Among the sesquiterpene lactones identified from the
plant species are artemisinin, arteannuin B (two to four
times) and artemisininic acid (seven to eight times) [2].
In order to exploit the by-product generated in the
process of atemisinin extraction from A. annua L.
our research group was prompted to study pharma-
cological activities of that material. Artemisinin, dihydro-
epideoxyarteannuin-B and deoxyartemisinin were isolated
from the sequiterpene lactone-enriched fraction obtained
from the crude ethanolic extract of A. annua L. These com-
pounds were tested on ethanol and indomethacin-induced
ulcer models. Artemisinin did not afford cytoprotection
under the experimental models tested. Only dihydro-
epideoxyarteannuin- B and deoxyartemisinin decreased the
ulcerative lesion index produced by ethanol and indometh-
acin in rats. These compounds did not demonstrate antiul-
cerogenic activity when tested on the ethanol-induced
ulcer model, with previous administration of indometh-
acin, suggesting that the antiulcerogenic activity was a con-
sequence of prostaglandin synthesis increase [7-10].
According to Chaturvedi (2011) [5] although, the exact
mechanism of action of sesquiterpene lactones are not
well understood they have been documented. Some au-
thors have reported explanations to account for the role
that those compounds play in anti-inflammatory activity
in different experimental models evaluated [1,11].
Based on previous work reported on anti-inflammatory
activity of sesquiterpene lactones we were prompted to fur-
ther study the antinociceptive and anti-inflammatory activ-
ity of the enriched sesquiterpene lactone fraction generated
in the production of artemisinin from A. annua L.
Methods
Phytochemistry
Material plant and fractionation
Artemisia annua L. leaves (hybrid CPQBA2/39 x PL5)
were collected from the experimental field of CPQBA/
UNICAMP. Voucher specimen is deposited at CPQBA/
UNICAMP under registration number 229. The hybrid
varieties (CPQBA2/39 and PL5) originated from clones of
Chinese SI/SII and Vietnamese FI/FII seeds adapted in
1991 at CPQBA experimental field, which were provided by
MEDIPLANT (Centre de Recherches SUR LES PLANTES
medicinal ET AROMATIQUES - Switzerland) responsible
for the work of improvement of seeds. The work in Brazil
was accomplished by Dr. Pedro Melillo Magalhães and
Dr. Glyn Mara Figueira.
This material was allowed to dry under air circulation
(40°C) and ground for use. The resulting powder (2000 g)was submitted to dynamics maceration with ethanol dur-
ing 2 hours (this procedure was repeated three times) [8].
A 10% lead acetate solution (1 L) was added to the
crude ethanolic extract (108 g) dissolved in ethanol
(100 mL). This mixture was allowed to stand at room
temperature overnight and filtered. The filtrate was ex-
tracted with chloroform (3 × 350 mL), dried over MgSO4,
filtered and dried under vacuum affording the sesquiter-
pene lactone enriched fraction (Lac-FR) (10 g - 9.3% yield)
[8,12]. This fraction (10 g) was purified on successive
column chromatography using silica gel (Merck 7734)
(5 × 60 cm) with hexane/ethyl acetate (99:1), Rf dihydro-
epideoxyarteannuin B: 0.65 between 500–950 mL,
[αD
20]: + 49.96° (c 0.025 g/mL, CHCl3); hexane/ethyl
acetate (99:2), Rf deoxyartemisinin: 0.61 between 1000–
1700 mL, [hexane/ethyl acetate (99:3), [αD
20]: −149.8° (c
0.045 g/mL, CHCl3); Rf artemisinin: 0.57 between 1750–
2550 mL, [αD
20]: + 80.93° (c 0.025 g/mL, CHCl3).
Fractions were monitored by thin layer chromatog-
raphy, eluent hexane/dichloromethane/methanol (20:79:1),
detection anisaldehyde reagent. The physical and spec-
tral data (mass, 1H-NMR, 13C-NMR) of compounds
isolated were consistent with those of artemisinin, deox-
yartemisinin and dihydro-epideoxyarteannuin-B reported
previously [8].
Chromatographic analysis
Development and validation of analytical method by
HPLC-IR for evaluation of artemisinin in A. annua L.
was accordingly to method previously developed and
validated by our research group [10]. The method was
based on high performance liquid chromatography, using a
CN column with mobile phase composed of methanol:
H2O 50:50 (V/V). The results showed that the method pre-
sented linearity from 50 to 1500 μg/ml.
Pharmacology
Drugs
All samples were diluted in a vehicle made of 1%
Tween80 (Sigma-Aldrich, U.S.A.) in 0.9% saline solution
(NaCl diluted in distilled water), considering each dif-
ferent chemical characteristics (hydrophilic/lipophilic).
The drugs pentobarbital (Cristália-Brazil), dexametha-
sone, carrageenan (Sigma-Aldrich, U.S.A.), morphine
hydrochloride (Johnson & Johnson, Brazil), indometh-
acin (Sigma-Aldrich, U.S.A.), naloxone hydrochloride
(Sigma-Aldrich, U.S.A.), and the reagents acetic acid and
formaldehyde from Sigma-Aldrich, U.S.A. - were used.
Animals
Male Swiss mice 25–35 g and male Wistar rats 150–
250 g body weights were kept at 25 ± 2°C in 12 h light–
dark cycles (light phase started at 7:00 am) maintained
(10 and 5 animals per cage, respectively) with water and
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arate groups of animals were used for each test, and they
were used only once in the experiments. Studies were
carried out in accordance with the Current Guidelines
for the Veterinary Care of Laboratory Animals - Joint
Working Group on Veterinary Care, Finland [13] and
were performed under the consent and surveillance of
the Institute of Biology Ethics Committee for Animal
Research (protocol 3016–1), University of Campinas -
Brazil. The number of animals and the intensity of the
noxious stimuli were the minimum necessary to obtain
reliable data.
Evaluation of acute toxicity
Groups of male Swiss mice (n = 3) and male Wistar rats
(n = 3) intraperitoneally treated with Lac-FR in 30, 75,
100, 300 and 500 mg/kg of a single dose. After adminis-
tration animals were observed during the first four hours
and daily during 14 days. On the 15th day all animals
were euthanized by cervical dislocation, followed by
necropsy and macroscopic observation of the organs
(OECD, [13]; Botham, [14]).
Evaluation of locomotor activity
The ambulatory behavior was assessed in an open-field
as described previously [15,16]. The apparatus consisted
of a plastic box measuring 45 × 45 × 20 cm, with the
floor divided into 9 equal squares (15 × 15 cm). The
number of squares crossed with all paws (crossing) was
counted in a 6-min session for each animal group (n = 6)
and considered indicative for the quantification of the
locomotor activity. For this purpose, mice were treated
intraperitoneally (i.p.) with the Lac-FR (75, 100 and
300 mg/kg), pentobarbital (35 mg/kg), or vehicle (10 ml/kg)
30 min beforehand.
Writhing test
Groups of Swiss mice (n = 6) were treated with vehicle
(10 ml/kg), or sesquiterpene lactones fraction (Lac-FR)
using 100 and 300 mg/kg doses under intraperitoneal
(i.p.) and oral (p.o.) routes. Writhings were induced by
an i.p. injection of 0.8% acetic acid solution (10 ml/kg),
30-min after i.p. treatments and 1 hour after p.o. treat-
ments. After this procedure, the numbers of writhings
(abdominal constrictions) were cumulatively counted
over 15 min, for nociception evaluation [14,15]. Data
represent the average of the total writhing observed per
dose administrated.
Formalin test
The formalin test was carried out as described by Woolfe
and Macdonald (1944) [17] with few changes in the proto-
col [15]. Formalin-induced pain behavior is biphasic: the
initial acute phase (0 - 5 min, neurogenic pain) is followedby a relatively short quiescent period, which is then
followed by a prolonged tonic response (25 - 40 min, in-
flammatory pain). Groups of mice (n = 6) were treated
i.p. with: vehicle (10 ml/kg, negative control), the positive
control for the neurogenic phase morphine (10 mg/kg,
determined previously), the positive control for the in-
flammatory phase indomethacin (30 mg/kg, determined
previously), and the dose–response of Lac-FR (30, 100
and 300 mg/kg (i.p.). After 30 min, animals were injected
with 20 μl of a formalin solution (formaldehyde 1.2%, in
PBS) into the plantar surface of the right hind paw. The
total time spent by animal licking or biting the injected
paw, an index of nociception, was recorded for the fol-
lowing 40 min.
Mechanical allodynia induced by Complete Freund’s
Adjuvant (CFA)
The procedures were developed and standardized in our
laboratory based on the method previously described by
Villeti et al. (2003) [18] with changes in protocol and
data analysis [19]. Different groups of rats, Wistar male
(n = 6), were used during the whole experiment and in-
flammation was induced with a solution of CFA (1 mg/ml
of heat killed Mycobacterium tuberculosis in 85% paraffin
oil and 15% mannide monooleate) injected (0.1 ml) into
the plantar surface of the right hind paw. The left hind
paw received the same volume of saline solution (NaCl
0.9% diluted in distilled water) in order to equalize the
sensibility of the animals caused by the injection. Mech-
anical allodynia was assessed using the Dynamic Plantar
Anesthesiometer apparatus (Ugo Basile, mod 37450,
Italy) which consisted of an elevated wire mesh platform
to allow access to the ventral surface of the hind paws. A
steel rod (diameter 0.5 mm) was pushed against the hind
paw with ascending force (touch stimulator). The force
ranged from 0 to 35 g over a 20-s period. When the ani-
mal withdrew the hind paw, the mechanical stimulus was
automatically stopped, and the force applied by the ani-
mal to withdraw the paw was recorded to the nearest
0.1 g. An allodynia score was determined after four con-
secutive measurements using the touch stimulator se-
quentially on the left and right hind paw and calculated
considering the formula below:
Left hind paw value=Right hind paw value ¼ Allodynia score
The basal score was measured before CFA injection
on day 0, and the animals considered for testing were
those with a mean value nearest to 1 (demonstrating no
significant difference between both paw stimuli). After
CFA injection, measurements were carried out consider-
ing two different phases, as follows: 4 h on day 0 (acute
pain) and 24 h (sub-acute pain). Vehicle (10 ml/kg), Lac-
FR were administered (30, 100 and 300 mg/kg, i.p.)
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possible anti-allodynic activity observed for each phase.
Carrageenan-induced mice paw edema
The anti-inflammatory properties were investigated by
using the carrageenan-induced edema model. The pro-
cedures used for this study were similar to those de-
scribed previously with some changes in the protocol
and data analysis [20,21]. Different groups of Swiss mice
(n = 6) were treated with the negative control (vehicle),
dexamethasone (1 mg/kg, i.p.-positive control) and Lac-FR
(100 and 300 mg/kg, i.p.) 2 h before administration of car-
rageenan (25 μL of a 3% solution carrageenan) injected
subcutaneously into the plantar region of the left hind paw.
Paw measurements (Plethysmometer 7140 Ugo Basile)
were taken at 2, 4, 6 and 24 hours. Results were expressed
as variations in time of the paw edema (mL).
Tail flick
Antinociception was determined using a tail-flick test as
described previously with few modifications on the
protocol [22,23]. In brief, the distal one third of the tail
was immersed in a water bath maintained at 48 ± 0.5°C.
Latency times until a tail-flick response (tail’s abrupt
withdrawal) were recorded before (baseline) and at dif-
ferent time points (0.5, 1, 2, 4 and 24 hours) after drug
treatment. Separate groups of six mice were treated
with morphine (5 mg/kg, i.p.), Lac-FR (30, 100, and
300 mg/kg, i.p.), or an equal volume of vehicle (10 ml/kg).
Aiming to evaluate the possible involvement of the opioid
system, in another set of experiments (time points 0.5, 1,
1.5, 2, and 4 hours) groups of six mice were treated with
morphine (5 mg/kg, i.p.), Lac-FR (100 mg/kg, i.p.), or
an equal volume of vehicle, in the presence and ab-
sence of the opioid antagonist naloxone (5 mg/kg, s.c.).
The antinociception response was presented as percent
maximal possible effect (%MPE) as defined by percent
maximal possible effect = 100% × (drug response time –
basal response time)/(cut-off time – basal response time).
A cut-off time of 15 s was applied to avoid tissue damage.
Statistical analysis
All results were submitted to one way analysis of vari-
ance (ANOVA) with repeated measurements, p ≤ 0.05
was considered the critical level for evaluating significant
difference between the control and treated groups, fol-
lowed by Tukey’s test (one-way ANOVA) or Bonferroni’s




A total 9.3% yield of sesquiterpene lactone fraction
(Lac-FR) resulted from the A. annua ethanol crude extractwith 1.72% artemisinin and 0.31% deoxiartemisinin content
determined by HPLC-IR.
Acute toxicity assessment
The Evaluation of Acute Toxicity determined the doses
to be used and the number of animals per group. The
administration of 30, 75, 100, 300 and 500 mg/kg doses
intraperitoneally, produced no mortality or behavioral
disorders in animals after 14-days observation. Lethargy
and ptosis, was observed for the 500 mg/kg i.p. dose up
to 1 h. Therefore that dose was not considered.
Evaluation of locomotor activity
Based on the acute toxicity evaluation, the ranges of
dosages tested in the open-field test were 75, 100,
and 300 mg/kg (i.p.). Therefore, the dose–response
curve designed for this experiment demonstrated that
(Figure 1) the negative control group receiving only
vehicle (10 mg/kg, i.p.) produced 89.17 ± 10.91 crossings,
and the positive control with pentobarbital (35 mg/kg, i.p.)
reduced to 16.50 ± 8.31 crossings (81.48% reduction).
The i.p. treatments with the fraction Lac-FR demon-
strated 84.83 ± 18.26 (75 mg/kg), 82.67 ± 7.62 (100 mg/kg),
and 41.67 ± 11.33 (300 mg/kg) crossings. The reduction
of crossings by 53.25% observed for the 300 mg/kg
group, compared to the negative control, indicated that
for the next antinociceptive experiments, this dosage
may not indicate only antinociception, but also cogni-
tive and/or muscular alterations. These results allowed
us to determine 100 mg/kg as the main dosage to be
considered in the antinociceptive properties of the
Lac-FR.
Writhing test
The non-specific writhing test was employed to ex-
plore the potential use of Lac-FR for pain releif when
tested with two different routes: oral (p.o.) and intra-
peritoneal (i.p.). The Figure 2 demonstrated that the
negative control group vehicle (10 ml/kg i.p.) pro-
duced 48.17 ± 5.21 writhings whereas the positive con-
trol indomethacin (10 mg/kg i.p.) showed a reduction
of 69.3% by 14.80 ± 2.81 writhings (p < 0.001). Lac-FR
samples were then administrated by both p.o. and i.p.
for kinectis comparisons. The treatments of Lac-FR
with 100 and 300 mg/kg p.o. doses demonstrated writhings
around 49.50 ± 7.5 and 34.60 ± 1.9, respectively. For the
i.p. administration with the same 100 and 300 mg/kg
doses, the number of writhings decreased to 3.0 ± 1.89
(93.7%) and zero (100%), respectively (p < 0.001). These
results showed that the oral treatment with Lac- did
not decrease significantly the abdominal constrictions
compared to the vehicle group, so that the oral treat-
ment was excluded of the next evaluations of the ani-
nociceptive properties.
Figure 1 Evaluation of the locomotor activity of Lac-FR. Number of crossings in the open-field test of animals treated with vehicle (10 ml/kg, i.p.),
pentobarbital (35 mg/kg, i.p.), and Lac-FR (75, 100, and 300 mg/kg) (i.p.). Results expressed as mean ± S.E.M. of 6 animals for experimental groups.
(ANOVA and Tukey’s test. ***p < 0.01).
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We next explored how effective the fraction Lac-FR
could be against neurogenic and inflammatory pain
stimuli under the formalin test. Results presented in
the first phase (Figure 3) demonstrating the neurogenic
response (0-5 min), showed that the negative control
group (vehicle 10 ml/kg, i.p.) produced a reaction time
of 89.17 ± 10.74 seconds. The positive controls morphine
(10 mg/kg, i.p.) 2.50 ± 1.58 seconds (97% reduction;
p < 0.001), and indomethacin (10 mg/kg, i.p.) 62.80 ±
9.47 seconds (no significant reduction). For this first phase,
the fraction Lac-FR showed reaction times by 48.40 ± 2.35
(30 mg/kg), 17.80 ± 3.27 (100 mg/kg) and 8.33 ± 1.82
(300 mg/kg) seconds reducing the pain stimuli around
45.72%, 80.03%, and 90.65%, respectively (p < 0.001).
Moreover, results presented in Figure 4 for the second
phase of the formalin test (25–40 min) representing the
inflammatory response, the group that received only ve-
hicle (i.p.) showed a reaction time of 94.60 ± 20.56 seconds.
The positive control groups morphine (10 mg/kg, i.p.), and
indomethacin (10 mg/kg, i.p.), reduced the reaction time
by 0 (100%) and 8.66 ± 4.84 seconds (97.8%), respectivelyFigure 2 The antinociceptive activity of Lac-FR in the writhing
test. Abdominal constrictions induced by acetic acid (0.8% in saline)
i.p. in mice previously treated (30 min) with control vehicle (10 ml/kg i.p.),
indomethacin-positive control (10 mg/kg i.p.) or Lac-FR (100 and
300 mg/kg) (i.p. and p.o.). Results expressed as mean ± S.E.M. of 6 animals
per experimental groups (ANOVA and Tukey’s test. ***p < 0.001).(p < 0.01). The i.p. treatments with the fraction Lac-FR
produced a significant reduction of the reaction times
compared to the control group, producing 71.60 ± 24.83
(30 mg/kg), 2.0 ± 0.94 (100 mg/kg), and zero (300 mg/kg)
seconds. On this phase, the treatment with 100 mg/kg and
300 mg/kg reduced stimuli by 97.8% and 100%, respect-
ively (p < 0.01), and motivated us to further explore the
antinociceptive properties of the fraction Lac-FR related to
inflammatory stimuli.
Mechanical allodynia assessment
Evaluating whether the fraction Lac-FR could be ef-
fective in the persistent pain caused by the intraplan-
tar injection of CFA in the mice, the mechanical
allodynia showed in the Figure 5 demonstrated the ef-
fectiveness of Lac-FR in a dose-dependent manner. Our
results showed that Lac-FR produced a significant anti-
allodynic activity reducing the allodynia score com-
pared to the control group vehicle (2.9 ± 0.12) during
the acute phase (4 h post CFA) of the test. The allodynia
scores observed for the fraction Lac-FR at 4 h time
were 1.76 ± 0.12 (30 mg/kg), 1.20 ± 0.11 (100 mg/kg),
and 1.04 ± 0.05 (300 mg/kg). The reductions of the allo-
dynia score on this phase were 40.93%, 59.73% and
65.10%, respectively (p < 0.001). In the sub-chronic phase
of the test (24 h post CFA), the control group vehicle
showed a 2.8 ± 0.08 allodynia score. The i.p. treatment
with the fraction Lac-FR presented allodynia scores
by 2.06 ± 0.31 (30 mg/kg), 1.42 ± 0.21 (100 mg/kg), and
1.06 ± 0.11 (300 mg/kg), reducing around 30.4%, 52.02%,
and 64.18% compared to the control group. This result
highlighted the activity of the fraction Lac-FR in inflam-
matory pain states, corroborating the phase II of the for-
malin test.
Carrageenan-induced paw edema
Aiming to evaluate the influence of the fraction Lac-FR
in the inflammatory edematogenic processes, the intra-
plantar injection of carrageenan producing edema was
Figure 3 Antinociceptive activity of Lac-FR related to chemical neurogenic pain stimulus. First phase (0–5 min) for reactivity time to the
intraplantar application of formalin (formaldehyde 1.2% in PBS) in the hind paw of mice previously treated i.p. (30 min) with control vehicle
(10 ml/kg i.p.) morphine (10 mg/kg i.p.) indomethacin (10 mg/kg i.p.) or fraction (30, 100, and 300 mg/kg i.p.). Results expressed as mean ± S.E.M.
of 6 animals for experimental groups (ANOVA and Tukey’s test. ***p < 0.001, **p < 0.01).
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that the fraction Lac-FR was significantly effective on re-
ducing edema compared to the control group within
2 h, 4 h, and 6 h post-carrageenan injection. These re-
ductions were observed after i.p. treatments with Lac-FR
100 and 300 mg/kg doses (p < 0.001). The most import-
ant conclusion of this test is the effectiveness of the frac-
tion not only in the perception of the inflammatory
stimuli, but also decreasing inflammatory mediators
causing edema.
Tail flick test
The first phase of the formalin test, revealing activity
under neurogenic stimulus, motivated us to further ex-
plore this mediation. For this purpose, the tail-flick wasFigure 4 Antinociceptive activity of Lac-FR related to chemical inflam
to the intraplantar application of formalin (formaldehyde 1.2% in PBS) in the
(10 ml/kg i.p.), morphine (10 mg/kg i.p.), indomethacin (10 mg/kg i.p.), or fra
animals for experimental groups (ANOVA and Tukey’s test. ***p < 0.001).employed. The time-points for the %MPE analysis were
0.5, 1, 2, 4, and 24 h after treatments, and fraction Lac-
FR was effective within 4 h of the test. The most import-
ant results are the ones observed after 1, 2, and 4 h
mainly with the 100 mg/kg (p < 0.001), which is a dosage
effective under thermal neurogenic stimulus with no in-
fluence in the open-field test (Figure 7).
The antinociceptive effect on the tail flick was also
evaluated using the opiod antagonist naloxone (Figure 8).
In this experiment only a 100 mg/kg Lac-FR dose was
tested to observe the antagonism effect after the pre-
treatment with naloxone. The %MPE increase of mor-
phine (5 mg/kg i.p.), morphine (5 mg/kg i.p.) associated
with naloxone (5 mg/kg s.c.), and Lac-FR (100 mg/kg i.p.)
associated with naloxone (5 mg/kg s.c.), after one hourmatory pain stimulus. Second phase (25–40 min) for reactivity time
hind paw of mice previously treated i.p. (30 min) with control vehicle
ction (30, 100, and 300 mg/kg). Results expressed as mean ± S.E.M. of 6
Figure 5 Determination of the allodynia score of Lac-FR in the CFA model of persistent pain. Graph demonstrating the decrease on
allodynia score related to the touch stimulation exerted on the surface of the left and right hind paws caused by injection of saline solution and
CFA (0.1 ml) respectively, producing persistent pain sensitization in rats treated with the Lac-FR (30, 100, and 300 mg/kg, i.p.), compared to the
control group (vehicle, 10 ml/kg i.p.). Results expressed as reduction score means ± S.E.M. of 6 animals for experimental group (ANOVA and
Bonferroni’s test. ***p < 0.001, *p < 0.05).
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naloxone), 16.62% (Lac-FR with naloxone), and 46.96%
(Lac-FR 100 mg/kg i.p.), respectively. With this result,
the influence of the pre-treatment with naloxone was
observed.
Discussion
During the last three decades sesquiterpenoid lactones
have emerged as one of the largest groups of plant prod-
ucts that have a broad range of biological activities
such as anti-inflammatory effect. Artemisia spp. charac-
teristically contains sesquiterpene lactones. SignificantFigure 6 Evaluation of the potential anti-inflammatory effects of Lac-
as paw edema (mL) per time after inflammation induction. Mice were pret
30 min before the intraplantar 2.5% carrageenan injection. Paw edema was
induction. (ANOVA and Bonferroni’s test. ***p < 0.001, **p < 0.01; *p < 0.05).antiinflammatory effects of some sesquiterpene lactones
isolated from Artemisia spp. have been reported [24].
Artemisinin (Qinghaosu), a natural compound identi-
fied in Artemisia annua L., is an effective drug mainly
used against cerebral malaria. The action of this drug is
immediate and parasitaemia in the treatment of drug-
resistant malaria is rapidly reduced, justifying the indus-
trial production of artemisinin. The worldwide demand for
artemisinin derivatives has increased due to the benefits
provided when compared to other medications employed
to treat malaria. This disease is still one of the major in the
world, causing physical and economic problems in tropicalFR. Effect of the Lac-FR on carrageenan-induced paw edema expressed
reated i.p. with Lac-FR (100 and 300 mg/kg), and vehicle (10 ml/kg i.p.),
evaluated in plethysmometer 2, 4, 6, and 24 hours after inflammation
Figure 7 The antinociceptive effects of Lac-FR against thermal stimulus. Effect of the Lac-FR on tail flick test. Mice were treated i.p. with Lac-FR
(30, 100 and 300 mg/kg i.p.), morphine (5 mg/kg i.p.), and vehicle (10 ml/kg i.p.), 0.5 h before evaluation. Evaluation times were 0.5, 1, 2, 4 and 24 hs.
(ANOVA and Bonferroni’s test. ***p < 0.001).
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tion of artemisinin derivatives. Our research group devel-
oped an industrial production of this potent antimalarial
drug, including strategies for enhancing yield using inex-
pensive and easy steps lowering the cost three-fold [9].
Nevertheless the large amount of by-product generated in
the process prompted studies on the extract’s pharmaco-
logical potencies [7,8].
According to Chadwick et al. (2013) [1] and Chaturvedi
(2011) [5], sesquiterpenes lactones, from Asteraceae, mayFigure 8 Evidences of the involvement of opioid system in the antino
morphine (5 mg/kg i.p.), morphine (5 mg/kg i.p.) associated with naloxone
(5 mg/kg s.c.), after one hour period were 70.21% (morphine), 21.94% (morph
100 mg/kg i.p.), respectively. Evaluation times were 0.5, 1, 2, 4, and 24 hs. (ANOplay a highly significant role in human health, both as part
of a balanced diet and as pharmaceutical agents. They are
described as the active constituents of a variety of medi-
cinal plants used in traditional medicine because of the
wide variety of biological and pharmacological activities
such as antimicrobial, cytotoxic, antiinflammatory, anti-
viral, antibacterial, antifungal activities, effects on the
central nervous and cardiovascular systems as well as
allergenic potency. Previously we reported the antiulcer ac-
tivity of the extract on ethanol and indomethacin-inducedciception caused by Lac-FR. The antinociceptive effect increase of
(5 mg/kg s.c.), and Lac-FR (100 mg/kg i.p.) associated with naloxone
ine with naloxone), 16.62% (Lac-FR with naloxone), and 46.96% (Lac-FR
VA and Bonferroni’s test. ***p < 0.001, **p < 0.01, *p < 0.05).
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and anti-inflammatory activity of Lac-FR evaluated in ani-
mal experimental models with mice and rats.
Acute toxicity evaluation was undertaken in animal ex-
perimental models using both mice and rats with 30, 75,
100, and 300 mg/kg doses not revealing any toxic effects.
Therefore those same doses were considered in the ones
uses throughout this study.
The antinociceptive activity was evaluated using writh-
ing, formalin, CFA-induced persistent pain, and tail-flick
tests. The writhing test determined the most convenient
route of administration (100 and 300 mg/kg i.p.), estab-
lishing that as route of choice for sample treatment
(Lac-FR) (Figure 1).
The open field test (Figure 2) was performed in order
to exclude the possibility that the antinociceptive action
could be related to non-specific disturbances in the loco-
motor activity of the animals [25]. That test is generally
believed to be a result from brain activation, which is
manifested as an excitation of central neurons and an in-
crease in cerebral metabolism [15,26]. The open field
test identified that doses up to 100 mg/kg (i.p.) did not
interfere in the locomotors activity (100 mg/kg).
The anti-inflammatory activity of Lac-FR was deter-
mined both by the second phase of the formalin test and
further by paw edema model induced by carrageenan.
The relationship of the central nervous system involved
with pain was evaluated by the tail flick model, in-
cluding evaluation of the opioid system using naloxone
as antagonist.
Acetic-acid induced pain (writhing test) is a screening
tool for the assessment of analgesic or antiinflammatory
properties of natural or synthetic compounds. The acid
acts indirectly by inducing the release of endogenous
mediators, which stimulate the nociceptive neurons. In-
flammatory pain transmission primarily involves periph-
eral polymodal receptors around small vessels which
signal to the CNS via sensory afferent C-fibers entering
the dorsal horn. However this chemical method has
good sensitivity but poor specificity allowing misin-
terpretation of the results, because this is an unspe-
cific stimulus for nociception, sensible to drugs with
different mechanisms. This problem can be avoided by
complementation with other nociception models re-
ported herein [15,27,28].
This assay provides a convenient stimulus for screen-
ing, because the intensity of response depends on the
interaction of several factors, neurotransmitters and
neuromodulators that determine nociception, such as
kinines, acetylcholine, substance P and prostaglandins.
Therefore, this model is responsive to analgesic substances
possessing the most varied action mechanisms, being sen-
sitive to drugs with analgesic activity such as aspirin, kinin
receptor antagonists (bradykinin, kallidin or T-kinin), andopioid analgesics with central or peripheral action. This
model permitted evaluation of antinociceptive activity
caused by both neurogenic and/or inflammatory pain
[25]. Thus, a positive result with this test does not neces-
sarily mean there is analgesic activity. Nevertheless, be-
cause all analgesics inhibit abdominal cramps, this method
is useful for sifting molecules whose pharmacodynamics
properties are unknown [29].
In order to determine if the antinociceptive activity
was through neurogenic or inflammatory stimulus the
formalin test was employed. Neurogenic pain is caused
by the direct activation of nociceptive nerve terminals,
whereas inflammatory pain is mediated by a combin-
ation of peripheral input and spinal cord sensitization.
Formalin produces significant increases in spinal levels
of different mediators related to both neurogenic (amino
acids, kinins) and inflammatory pathways (prostaglandins,
leukotrienes) [15,16].
Results presented herein present consistent data to
support antinociceptive activity in both the acute
phase reflecting direct activation of nociceptors and
late phase reflecting inflammation. In the first 5 minutes
(phase 1) a significant decreased was observed for 100 and
300 mg/kg Lac-FR compared to morphine (10 mg/kg, i.p.)
positive control (Figure 3). These findings suggest that the
activity of the sample under test might have a relationship
with desensitization of receptor sensitive to chemical
stimulus. The second phase also demonstrated a significant
reduction of the reaction time suggesting that Lac-FR has a
mechanism of action that act through both neurogenic and
anti-inflammatory mediators.
To better understand the inflammatory pain pathway
the CFA-induced persistent pain model was evaluated.
Persistent pain caused by CFA intraplantar injection in-
volves central sensitization due to the release of multiple
inflammatory and pain mediators that account for sensi-
tivity increase of both peripheral sensory afferents at the
injury site, and in the central nervous system [19,30].
The arrival of sensorial information from nociceptors
into the dorsal horn considerably alters the level of ac-
tivity within the cord as both excitatory and inhibitory
systems can impinge upon spinal neuronal activity. This
forms the basis of central hypersensitivity which results
in increased responsiveness of dorsal horn neurons, often
observed in persistent inflammatory and neuropathic states
of pain [19,31].
The three Lac-FR doses evaluated (30, 100, and
300 mg/kg i.p.) decreased the mechanical allodynic
stimulus. The two higher doses showed significant activity
both in the acute (4 h after CFA injection) and sub-acute
phase (24 h after CFA injection) (Figure 5).
The intraplantar injection of carrageenan induces both
hipernociception and edema formation [32]. This in-
flammatory method has become a widely used model for
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geenan evokes a very inflammatory and nociceptive re-
sponse characteristic, which is mediated by different
groups of endogenous substances that stimulate chemo
sensitive nociceptors, thus playing a major role in the
development of inflammatory pain [19,33,34]. Sample
Lac-FR with 100 and 300 mg/kg (i.p.) showed decreased
paw edema after 2 h time suggesting a relationship with
inflammatory mediators such as prostaglandins, leukotri-
enes among others (Figure 6).
Considering that sample Lac-FR demonstrated activity
in phase 1 of formalin test, that demonstrated a rela-
tionship with neurogenic pain, the tail flick model was
employed to verify if the sample had the capacity to re-
duce thermal stimulus. Both the samples (100 and
300 mg/kg i.p.) and morphine (5 mg/kg i.p.) demon-
strated the same effect after elapse of an hour. Thereafter
Lac-FR (300 mg/kg i.p.) and positive control (morphine)
maintained the same antinociception index up to four
hours of experimental time. These finding suggest that the
sample has an antinociceptive pathway with both periph-
eral characteristics and central nervous system component
(Figure 7). Moreover employing the same assay the pos-
sible involvement of opioid mechanism was evaluated
injecting naloxone, an opioid antagonist reverted the anal-
gesic activity.
The differences in activity among individual sesquiter-
pene lactones may be explained by differences in the
number of alkylating elements, lipophilicity, molecular
geometry, and the chemical environment of the target
sulfhydryl group. Although, the exact mechanism of ac-
tion of sesquiterpene lactones are not well known, they
have been documented through the various published
reports on the biological activity displayed by the majority
of sesquiterpene lactones with α-methylene-γ-lactones and
α,β-unsaturated cyclopentenone ring [5].
The presence of such groups in sesquiterpene lactones
has been significant in eliciting potent inhibitory activity
against iNOS-dependent [11]. The most widely published
class of natural products cited as inhibitors of NF-ƙB
(nuclear factor kappa B) are the sesquiterpene. NF-ƙB is a
protein that mediates immune response in humans by
controlling response of other effectors such as cytokines,
inflammatory molecules and cell adhesion molecules [1,5].
The current understanding of the NF-ƙB cascade provides
the biochemist and natural product scientist with a tanta-
lising opportunity of potential targets [11]. Other theories
on the anti-inflammatory effects of sesquiterpene lactones
include activation of p53 and an increase in ROS as cyto-
toxic effects of sesquiterpene lactones [1].
The results described herein are the first report of the
antinoniceptive and antiinflammatorry activity of Lac-FR
obtained from A. annua extract with 1.72% artemisinin
and 0.31% deoxiartemisinin content.Conclusions
The most relevant findings of the present work were
that Lac-FR obtained from Artemisia annua L. extract
have potential to be used for pain relief revealed by
chemical-induced nociception assays in mice; the i.p.
treatment produced a significantly antinociceptive effect
in the writhing test and produced a relevant reduction
in the reaction time of the animals in both phases of the
formalin test. Also, the i.p. treatment significantly re-
duced the sensitivity to mechanical allodynia stimulus
and reduced the paw edema caused by carrageenan in-
jection. Finally the i.p treatment promoted high antinoci-
ceptive activity in tail flick model suggesting relationship
with the opioid system. Further studies are being under-
taken to elucidate the active components involved with the
antinociceptive activity as well as evaluate synergy effect
that is seen by combination of substances that is greater
than would be expected from consideration of individual
contributions.
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